Ketto cofounders launch MetaGO for obesity care

Key Takeaways

• MetaGO combines diagnostic testing, teleconsultations, nutrition coaching, and GLP-1 medications in a single platform
• The startup tracks 35+ biomarkers per user and assigns specialists including endocrinologists and cardiologists
• Ketto founders bring experience from building India's largest health crowdfunding platform

Actor Kunal Kapoor and Ketto cofounders Varun Sheth and Zaheer Adenwala have launched MetaGO, a healthtech startup offering doctor-led weight management programs with GLP-1 medications. The platform targets obesity and related metabolic conditions, combining diagnostic testing, teleconsultations, and personalized nutrition coaching.

The founding team's thesis is simple: intervene before patients need emergency care. Sheth and Adenwala spent 14 years at Ketto, India's largest health crowdfunding platform, watching families arrive after years of diabetes or obesity had already progressed into crisis. MetaGO is their attempt to flip the sequence.

How does MetaGO's model work?

Every user starts with a diagnostic evaluation tracking over 35 biomarkers. From there, specialists design an individualized treatment plan. The company says it assigns endocrinologists and cardiologists based on each user's metabolic profile, not generic protocols.

The prescription GLP-1 medications are the commercial centerpiece. These drugs, which include semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), have driven a global weight-loss boom. MetaGO bundles them with ongoing physician oversight and coaching, positioning itself as a guided alternative to standalone prescriptions.

"Fourteen years of building Ketto teaches you to see patterns. We met thousands of families at some of the hardest moments of their lives, often after years of diabetes, obesity, or other metabolic conditions had progressed," Kapoor said. "Over time, it became clear that many of those conditions had begun developing years before anyone needed medical treatment. That's what led to MetaGO."

Why metabolic health, why now?

India has over 200 million obese citizens and 77 million people living with Type 2 diabetes, the second-highest count globally. One in four Indians is affected by some form of metabolic disorder. The market conditions are obvious. The question is execution.

MetaGO recently ran a free metabolic health camp for Mumbai Police, providing blood tests and physician consultations. The company says it plans more outreach to professional groups as a way to build awareness around early intervention. It's a low-cost acquisition channel: find concentrated populations with health risk factors and screen them for free.

The healthtech 2.0 wave

MetaGO joins a cohort of startups moving past basic telemedicine into what investors are calling "healthtech 2.0." The common thread is personalization, prevention, and optimization rather than reactive treatment.

Temple, a health wearables company backed by Zomato founder Deepinder Goyal, is building devices for continuous monitoring. FOXO offers personalized treatment protocols. Sychedelic is developing AI-powered headphones for wellness applications. Each bets that the next wave of healthcare value will come from keeping people healthy, not treating them after they're sick.

The funding follows. 4baseCare, a genomics startup building personalized cancer treatments, closed a Rs 128 crore Series B round recently. Practo cofounder Shashank ND launched Cent, a preventive healthcare intelligence company, which raised $5 million in seed funding earlier this year.

What the Ketto track record means

Sheth and Adenwala have raised over $50 million for Ketto since founding it. The platform has facilitated more than Rs 2,500 crore for medical causes. That's relevant for two reasons.

First, they've seen thousands of medical emergencies up close. They understand which conditions drive catastrophic costs and which interventions could have prevented them. Second, they know how to build consumer-facing health platforms. Ketto required user trust, payment processing, and regulatory compliance. MetaGO needs the same.

Kapoor adds celebrity reach. He's known for fitness advocacy and brings distribution to an audience that might not otherwise engage with metabolic health messaging.

What's still unclear

MetaGO hasn't disclosed pricing, funding, or user targets. The GLP-1 medications themselves are expensive. Semaglutide and tirzepatide can cost Rs 10,000 to Rs 30,000 per month in India depending on dosage and brand. Whether MetaGO's bundled model makes these accessible or remains a premium offering will determine its addressable market.

The startup also hasn't detailed its physician network or teleconsultation infrastructure. Scaling doctor-led care is notoriously difficult. Practo, Mfine, and others have struggled with physician supply constraints.

Frequently Asked Questions

What is MetaGO?

MetaGO is a healthtech startup founded by Kunal Kapoor and Ketto cofounders Varun Sheth and Zaheer Adenwala. It offers doctor-led weight management programs combining diagnostics, teleconsultations, nutrition coaching, and GLP-1 medications.

How does MetaGO's treatment program work?

Users begin with diagnostic testing covering 35+ biomarkers. Specialists including endocrinologists and cardiologists then design personalized treatment plans, which may include prescription GLP-1 medications and ongoing coaching.

Who are the founders of MetaGO?

MetaGO was cofounded by Bollywood actor Kunal Kapoor and Ketto cofounders Varun Sheth and Zaheer Adenwala. The Ketto team brings experience from building India's largest health crowdfunding platform.

What is healthtech 2.0?

Healthtech 2.0 refers to a wave of startups focused on prevention, personalization, and longevity rather than reactive treatment. Examples include MetaGO, Temple (health wearables), and 4baseCare (personalized cancer treatment).

Has MetaGO raised funding?

MetaGO has not publicly disclosed funding details. The company launched without announcing investment amounts or lead investors.

Source: Inc42 Media / Gaurav Bagur